Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 12, 2011 - Issue 15
Submit an article Journal homepage
417
Views
13
CrossRef citations to date
0
Altmetric
Reviews

Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors

Robert A KlonerThe Heart Institute, Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, CA 90017-2395, USA+1 213 977 4040; +1 213 977 4107; [email protected]
, MD PhD,
Gary Comstock Pfizer Inc., NY, USA
, MD,
Laurence A Levine Rush University Medical Center, Chicago, IL, USA
, MD,
Steven Tiger Complete Healthcare Communications, Inc., Chadds Ford, PA, USA
, PA &
Vera J Stecher Pfizer Inc., NY, USA
, PhD
Pages 2297-2313 | Published online: 21 Jul 2011

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mohammad Amin Rezvanfar, Hamid Reza Rahimi & Mohammad Abdollahi. (2012) ADMET considerations for phosphodiesterase-5 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 8:10, pages 1231-1245.
Read now
Antonio Cocchiarella. (2012) Partial motor restoration upon administration of sildenafil: a case study. Developmental Neurorehabilitation 15:1, pages 39-43.
Read now

Articles from other publishers (11)

Saurabh Kumar Chhonker, Divya Rawat & Raj Kumar Koiri. (2022) Repurposing PDE5 inhibitor tadalafil and sildenafil as anticancer agent against hepatocellular carcinoma via targeting key events of glucose metabolism and multidrug resistance. Journal of Biochemical and Molecular Toxicology 36:8.
Crossref
Catalano, Panza, Augimeri, Giordano, Malivindi, Gelsomino, Marsico, Giordano, Győrffy, Bonofiglio, Andò & Barone. (2019) Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression. Cancers 11:11, pages 1740.
Crossref
I. A. Tyuzikov, A. V. Smirnov, L. V. Smirnova & I. V. Lesnikova. (2019) Non-classical effects of sildenafil in clinical medicine: an interdisciplinary approach. Medical Council:21, pages 192-202.
Crossref
Ines Barone, Cinzia Giordano, Daniela Bonofiglio, Sebastiano Andò & Stefania Catalano. (2017) Phosphodiesterase type 5 and cancers: progress and challenges. Oncotarget 8:58, pages 99179-99202.
Crossref
Stefania Catalano, Antonella Campana, Cinzia Giordano, Balázs Győrffy, Roberta Tarallo, Antonio Rinaldi, Giuseppina Bruno, Aurora Ferraro, Francesco Romeo, Marilena Lanzino, Fabio Naro, Daniela Bonofiglio, Sebastiano Andò & Ines Barone. (2016) Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy. Clinical Cancer Research 22:9, pages 2271-2282.
Crossref
Ines Barone, Cinzia Giordano, Daniela Bonofiglio, Stefania Catalano & Sebastiano Andò. (2015) Phosphodiesterase Type 5 as a Candidate Therapeutic Target in Cancers. Current Pathobiology Reports 3:3, pages 193-201.
Crossref
Giuseppe Defeudis, Daniele Gianfrilli, Chiara Di Emidio, Riccardo Pofi, Dario Tuccinardi, Andrea Palermo, Andrea Lenzi & Paolo Pozzilli. (2015) Erectile dysfunction and its management in patients with diabetes mellitus. Reviews in Endocrine and Metabolic Disorders 16:3, pages 213-231.
Crossref
Anindita Das, David Durrant, Fadi N. Salloum, Lei Xi & Rakesh C. Kukreja. (2015) PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacology & Therapeutics 147, pages 12-21.
Crossref
Dafydd R. Owen. 2014. Phosphodiesterases and Their Inhibitors. Phosphodiesterases and Their Inhibitors 9 28 .
Linda Vignozzi, Sandra Filippi, Annamaria Morelli, Paolo Comeglio, Ilaria Cellai, Erica Sarchielli, Elena Maneschi, Rosa Mancina, Mauro Gacci, Gabriella Barbara Vannelli & Mario Maggi. (2012) Testosterone/Estradiol Ratio Regulates NO‐Induced Bladder Relaxation and Responsiveness to PDE5 Inhibitors. The Journal of Sexual Medicine 9:12, pages 3028-3040.
Crossref
Jun Kotera, Hideki Mochida, Hirotaka Inoue, Tsunehisa Noto, Kotomi Fujishige, Takashi Sasaki, Tamaki Kobayashi, Koki Kojima, Shiyin Yee, Yasuhiro Yamada, Kohei Kikkawa & Kenji Omori. (2012) Avanafil, a Potent and Highly Selective Phosphodiesterase-5 Inhibitor for Erectile Dysfunction. Journal of Urology 188:2, pages 668-674.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.